Most claims about medical cannabis rest on thin evidence. Epilepsy is the exception. In June 2018 the US Food and Drug Administration approved Epidiolex, a purified plant-derived cannabidiol oral solution, the first approval of a drug derived from cannabis in the United States.
That is a genuine milestone, and it is also narrower than the way it usually gets described. Understanding what was approved, and what was not, is the whole point of this page.
What Was Actually Approved
Epidiolex was approved for seizures associated with two rare, severe childhood-onset epilepsy syndromes: Lennox-Gastaut syndrome and Dravet syndrome, initially in patients aged two and older. In 2020 the FDA added seizures associated with tuberous sclerosis complex.
Three specific conditions. Not epilepsy generally, and not adult focal epilepsy. The approval rests on randomised placebo-controlled trials that showed reductions in seizure frequency against placebo in these populations.
Two details matter for anyone reading the label:
The Dosing, and Why It Explains Consumer Disappointment
Epidiolex is typically started around 5 mg per kilogram of body weight per day, divided into two doses, then titrated upward to roughly 10 mg/kg/day and in some cases 20 mg/kg/day depending on response and tolerability.
Run that arithmetic for a 20 kg child and you get 100 mg to 400 mg of CBD per day. For a 70 kg adult the equivalent range would be several hundred milligrams to over a gram daily.
Now compare that to a retail CBD product containing 25 mg per serving. The gap is not marginal, it is one to two orders of magnitude. When someone reports that CBD did nothing for a seizure disorder, dose is very often the explanation rather than the compound.
Drug Interactions Are the Real Clinical Story
CBD is not a benign add-on to an existing anti-epileptic regimen, and this is where prescribing supervision earns its place.
None of that is a reason to avoid treatment. It is a reason not to run it without a neurologist.
How CBD Might Work Here
The mechanism is not settled, and notably it does not appear to run through CB1 receptors the way THC does. Proposed contributors include antagonism at GPR55, effects on TRPV1 channels, and modulation of adenosine signalling. Anti-inflammatory and neuroprotective effects have also been proposed.
The honest position is that CBD is an approved anticonvulsant whose mechanism of action remains partly unresolved. That is not unusual in epilepsy pharmacology.
Where THC Does Not Fit
THC is not part of the approved treatment, and the reasoning is not squeamishness. Evidence for THC as an anticonvulsant is weak, and there are reports of high-THC exposure lowering seizure threshold in some people. Cognitive effects in a developing brain are a further concern in paediatric epilepsy specifically.
Whole-plant high-THC cannabis and approved CBD medication are not interchangeable options here.
The Artisanal Oil Problem
Before Epidiolex, families with children facing catastrophic epilepsy turned to artisanal CBD preparations, and the 2013 coverage of Charlotte Figi's case moved public opinion faster than any trial did. That history is real and it drove the research.
It also exposed a supply problem that has not fully gone away. Unregulated CBD products have repeatedly been found to be mislabelled in both directions, containing less CBD than claimed or unexpected THC. For a seizure patient, inconsistent dosing between bottles is not a minor inconvenience, it undermines the treatment.
What the Reviews Say About Cannabis Broadly
The 2017 National Academies of Sciences, Engineering, and Medicine review found insufficient evidence to support or refute cannabis or cannabinoids as effective for epilepsy at that time. The Epidiolex trials landed around and after that assessment, which is why the evidence for purified CBD in specific syndromes now sits well ahead of the evidence for cannabis in epilepsy generally.
Keeping those two claims separate is the single most useful thing to take from this topic.
Bottom Line
A cannabis-derived compound is an approved epilepsy medicine, for three named syndromes, at doses far higher than consumer products deliver, with interactions that require monitoring. That is a real and meaningful result. It is not evidence that cannabis treats epilepsy in general, and it is not a reason to substitute a retail CBD bottle for prescribed anti-epileptic medication.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any health-related decisions.